2.96
Goodrx Holdings Inc stock is traded at $2.96, with a volume of 530.41K.
It is up +3.14% in the last 24 hours and up +7.25% over the past month.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
See More
Previous Close:
$2.87
Open:
$2.89
24h Volume:
530.41K
Relative Volume:
0.38
Market Cap:
$1.00B
Revenue:
$787.89M
Net Income/Loss:
$20.56M
P/E Ratio:
50.60
EPS:
0.0585
Net Cash Flow:
$96.54M
1W Performance:
-5.73%
1M Performance:
+7.25%
6M Performance:
+15.62%
1Y Performance:
-40.44%
Goodrx Holdings Inc Stock (GDRX) Company Profile
Name
Goodrx Holdings Inc
Sector
Industry
Phone
(855) 268-2822
Address
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, HQY, TEM, TXG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
GDRX
Goodrx Holdings Inc
|
2.96 | 1.00B | 787.89M | 20.56M | 96.54M | 0.0585 |
|
VEEV
Veeva Systems Inc
|
186.24 | 30.25B | 3.32B | 941.65M | 1.64B | 5.6161 |
|
BTSG
Brightspring Health Services Inc
|
72.91 | 14.31B | 13.65B | 169.86M | 412.12M | 1.0758 |
|
HQY
Healthequity Inc
|
94.64 | 7.91B | 1.34B | 230.70M | 440.96M | 2.6695 |
|
TEM
Tempus Ai Inc
|
42.69 | 7.69B | 1.36B | -302.91M | -219.93M | -1.7182 |
|
TXG
10 X Genomics Inc
|
46.27 | 5.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-09-25 | Initiated | Barclays | Underweight |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Aug-09-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-23-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-16-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-25-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-23 | Upgrade | DA Davidson | Neutral → Buy |
| Jul-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Dec-01-22 | Initiated | Citigroup | Buy |
| Nov-04-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-07-22 | Initiated | Truist | Hold |
| Aug-12-22 | Initiated | DA Davidson | Neutral |
| Jun-10-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-06-22 | Resumed | BofA Securities | Buy |
| Jun-01-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-10-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-10-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-10-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-11-22 | Initiated | Wells Fargo | Equal Weight |
| Apr-07-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Neutral |
| Mar-15-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-22 | Reiterated | Barclays | Overweight |
| Mar-01-22 | Reiterated | BofA Securities | Neutral |
| Mar-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-01-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-01-22 | Reiterated | Evercore ISI | Outperform |
| Mar-01-22 | Reiterated | Goldman | Buy |
| Mar-01-22 | Reiterated | JP Morgan | Underweight |
| Mar-01-22 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-01-22 | Reiterated | SVB Leerink | Outperform |
| Jan-07-22 | Initiated | Goldman | Buy |
| Dec-21-21 | Initiated | Stephens | Overweight |
| Dec-02-21 | Initiated | Jefferies | Buy |
| Aug-31-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-13-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-28-21 | Initiated | Robert W. Baird | Neutral |
| Apr-06-21 | Resumed | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Guggenheim | Buy |
| Nov-19-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-19-20 | Initiated | Barclays | Equal Weight |
| Oct-19-20 | Initiated | BofA Securities | Neutral |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Oct-19-20 | Initiated | Credit Suisse | Outperform |
| Oct-19-20 | Initiated | Deutsche Bank | Hold |
| Oct-19-20 | Initiated | Goldman | Neutral |
| Oct-19-20 | Initiated | JP Morgan | Neutral |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
| Oct-19-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-19-20 | Initiated | SVB Leerink | Outperform |
| Oct-19-20 | Initiated | UBS | Buy |
View All
Goodrx Holdings Inc Stock (GDRX) Latest News
GoodRx Holdings Inc (GDRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GoodRx Holdings Inc (GDRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GoodRx Holdings Inc (GDRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GoodRx Holdings Inc (GDRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GoodRx Holdings Inc (GDRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GoodRx Holdings Inc (GDRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GDRX|GoodRx Holdings Inc|Price:2.870|Chg%:-0.060 - TradingKey
Teladoc, GoodRx shares fall on OpenAI health feature launch By Investing.com - Investing.com South Africa
GoodRx (GDRX) Receives Positive Analyst Outlook with $4 Price Ta - GuruFocus
GoodRx Holdings Inc (GDRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GoodRx (GDRX): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Navigating Healthcare with a 1.30% Upside Potential - DirectorsTalk Interviews
Thomas (tc) Chan Net Worth (2026) - GuruFocus
GoodRx Holdings Inc (FRA:8GH) Stock Price, Trades & News - GuruFocus
Form 4 Goodrx Holdings Inc For: 16 July By Investing.com - Investing.com Nigeria
GoodRx Holdings (GDRX) officer exercises RSUs, withholds shares for taxes - Stock Titan
GoodRx Holdings (NASDAQ: GDRX) insider converts RSUs, covers tax with stock - Stock Titan
GoodRx (GDRX) CAO exercises RSUs and withholds shares for taxes - Stock Titan
Frontier tech research, news & data - MLQ.ai
GoodRx (GDRX) Q4 2025 earnings summary - Quartr
GDRX or HQY: Which is the better value stock right now? - MSN
GoodRx (GDRX) Stock Trades Up, Here Is Why - Yahoo Finance
GoodRx Holdings (GDRX) Pharma Growth Story Meets A Small Fair Value Gap - Yahoo Finance
GoodRx (GDRX) Stock Looks Full On Earnings But Mixed On Value - Yahoo Finance
GoodRx (GDRX) Q1 2025 earnings summary - Quartr
GoodRx sets date for Q2FY26 earnings release - scanx.trade
Press Release: GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call - Moomoo
GoodRx sets Aug. 5 earnings release, Aug. 6 call - Stock Titan
GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call - Business Wire
GoodRx (GDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
GDRX or HQY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is GoodRx (GDRX) Stock Undervalued Right Now? - Yahoo Finance
Earnings call transcript: GoodRx Q1 2026 revenue exceeds forecasts - Investing.com
GDRXGoodRx Holdings Inc Options - Finviz
GDRX.O - Reuters
3 Penny Stocks Under $8B Market Cap Worth Watching - simplywall.st
Enterprise value to revenue forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
GoodRx Holdings Inc (GDRX) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Enterprise value to revenue forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Price to sales forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Price to sales forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
GoodRx Holdings, Inc. Class A Actuals & Estimates (NASDAQ:GDRX) - TradingView
Enterprise value to EBITDA forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
GDRX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Enterprise value to EBIT forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Price to earnings forward of GoodRx Holdings, Inc. – NASDAQ:GDRX - TradingView
Enterprise value to EBIT forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Price to earnings forward of GoodRx Holdings, Inc. – BOATS:GDRX - TradingView
Is It Time To Consider Buying GoodRx Holdings, Inc. (NASDAQ:GDRX)? - Moomoo
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating - Moomoo
Goodrx Holdings Inc Stock (GDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Goodrx Holdings Inc Stock (GDRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):